August 25, 2004

PATENT APPLICATION **DOCKET NO.: 2629.1003-008**

IN THE UNITED STATES PATENT AN MARK OFFICE

Applicant:

Sudhir V. Shah

Application No.:

10/820,478

Group Art Unit:

1654

Filed:

April 8, 2004

Examiner:

Not Assigned

Confirmation No.: .

8698

Title:

DIAGNOSIS AND TREATMENT OF HUMAN KIDNEY DISEASES

CERTIFICATE OF MAILING OR TRANSMISSION
I hereby certify that this correspondence is being deposited with the United States
Postal Service with sufficient postage as First Class Mail in an envelope addressed
to Commissioner for Patents, P.O.Box 1450, Alexandria, VA 22313-1450, or is
being facsimile transmitted to the United States Patent and Trademark Office on:
Date Signature
Jennifer quartier
Typed or printed name of person signing certificate

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:	
This I []	information Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)
[X]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
[]	under 37 CFR 1.97(c) together with either: [] a Statement under 37 CFR 1.97(e), as checked below, or [] a \$180.00 fee under 37 CFR 1.17(p), or
[]	(After the 37 CFR 1.97(d) together with:
	[] a Statement under 37 CFR 1.97(e), as checked below, and [] a \$180.00 fee under 37 CFR 1.17(p), or
[]	(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee) under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee)

Statem	ient Und	der 37 C	FR 1.97(e)				
[]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or						
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.						
Staten	nent Und	der 37 C	(Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000				
[]	Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.						
[X]	Enclosed herewith is form PTO-1449:						
	[X]	Copies	of the cited references (AP, AQ, AW5, AX5) are enclosed.				
		[X]	Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.				
	[] Copies of the cited references are enclosed except those entered in prior application, U. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlied application contains copies of the cited references.]						
	[X] Previously cited references (AL-AO, AY3, AZ3, AR4) were cited in the enclosed International Search Report in a related foreign application.						
	[X] The "concise explanation" requirement (non-English references) for reference AQ unde 37 CFR 1.98(a)(3) is satisfied by:						
		[]	the explanation provided on the attached sheet.				
	•	[]	the explanation provided in the Specification.				
		[]	submission of the enclosed International Search Report.				
		[]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.				
		$\Gamma \mathbf{Y}$ 1	the enclosed English language abstract				

[]	Applic	ant requests that the following n	on-published pending applic	cations be considered:			
Examiner's Initials							
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []			
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []			
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []			
		Examiner	Date	_			
	[]	A copy of each above-cited app	olication, including the curre	nt claims, is enclosed.			
	[]	A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed.	olication, including the curre on, U.S. Application No. [nt claims, is enclosed, except], to which priority under			
The Ex	kaminer ices wei	is requested to return a copy of re considered with the next office	the above list of pending ap	plications indicating which			
It is re	quested	that the information disclosed h	nerein be made of record in the	his application.			
Metho	d of pay	ment:					
[]	A checacom	ck for the fee noted above is enc panying Reply. A copy of this S	losed, or the fee has been inc Statement is enclosed.	cluded in the check with the			
[]		lease charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is nelosed.					
[X]	Please	charge any deficiency in fees ar	nd credit any overpayment to	Deposit Account 08-0380.			
		I	Respectfully submitted,				
		I	HAMILTON, BROOK, SMI	TH & REYNOLDS, P.C.			
			Mary K. Murray Registration No.: 47,813 Telephone: (978) 341-0036 Facsimile: (978) 341-0136	Munay			
Conco Dated:		01742-9133 Just 27, 2004					

OIPE	ATTORNEY DOCKET NO.	APPI	LICATION NO 820,478	Sheet 1 of 1	
SECOND SUPPLEMENTAL INFORMATION SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2629.1003-008		FILING DATE April 8, 2004		
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION August 31, 2004 (Use several sheets if necessary)	EXAMINER Not Assigned	CONFIRMA 8698	ATION NO.	GROUP 1654	

				S. PAT	ENT DOCUMI	IE DATE /	NAME OF PATENT	EE OR APPLICA	TU
M- \	REF. NO.		DOCUMENT NUMBER Number-Kind Code (if known)		PUBLICATION DATE MM-DD-YYYY				
		+-	584,482		08-04-1987		Green		
	AE				09-10-1991		Suzuki Martin et al.		
	AF		047,329						
	AG		206,849 B1		05-07-2002		Schwartz		
	AH		,383,817 B2		07-08-2003		Torti et al.		
	Al		,589,966 B1		03-16-2004		Ranganathan et al.		
	AJ	6	5,706,287 B2	DEIC	N PATENT DO				
			POCUMENT NUMBER		DATE M-DD-YYYY	NAME OF PATENTE OF CITED DO	E OR APPLICANT OCUMENT	TRANSLA YES	NO NO
			Country Code-Number-Kind Code (if known)			L. b. dahaeya			X
	1	AP	WO 00/54784		9-21-2000	Aripkohodzhaeva Santen Pharmaceuticals Co., Ltd		X (Abstract)	
AQ		AQ			Dai Ichi Seiyaku		i Co., Lia.		
_			OTHER DOCUMEN	NTS (In	cluding Author,	Title, Date, Pertinent	Pages, Etc.)		
AW5 Fernández-Real, J.M., et al., "Cross			Cross-T	Talk Between	Iron Metabolism ar	nd Diabetes," Did			
		AX5	Nitenberg, A., et al., "Coronary Microvascular Adaptation to Myocardial Metabolic Demand Can Be Restored by Inhibition of Iron-Catalyzed Formation of Oxygen Free Radicals in Type 2 Diabetic Patients," Diabetes, 51:813-818, 2002						
		-							
		_							

	DATE CONSIDERED
EXAMINER	
2 (UODMA/JIBSR05:iManage;470812;1	